References
- Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29 (6 Suppl. 16): 15–18.
- Mangi MH, Newland AC. Angiogenesis and angiogenic mediatorsin haematological malignancies. Br J Haematol 2000; 111: 43–51.
- Molica S, Vacca A, Levato D, Merchionne F, Ribatti D. Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res 2004; 28: 321–324.
- Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006; 33: 174–185.
- Kay NE, Bone ND, Tschumper RC et al. B-CLL cells are capableof synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002; 16: 911–919.
- Till KJ, Spiller DG, Harris RJ et al. CLL, but not normal, B cellsare dependent on autocrine VEGF and alpha4beta 1 integrin for chemokine-induced motility on and through endothelium. Blood 2005; 105: 4813–4819.
- Hfittmann A, Klein-Hitpass L, Thomale J et al. Gene expression signatures separate B-cell chronic lymphocytic leukaemia prog-nostic subgroups defined by ZAP-70 and CD38 expression status. Leukemia 2006; 20: 1774–1782.
- Maffei R, Marasca R, Martinelli S et al. Angiopoietin-2 expressionin B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. Leukemia 2007; 21: 1312–1315.
- Martinelli S, Maffei R, Castelli I et al. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leuk Res 2008; 32: 593–597.
- Cheson BD, Bennett JM, Greyer M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lym-phocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
- Universal ProbeLibrary [Internet]. Roche Applied Science; 1996–2008 [cited 2008 Sep 20]; Available from: http://www.universal-probelibrary.com
- Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775.
- Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.
- Pekova S, Markova J, Pajer P, Dvorak M, Cetkovsky P, Schwarz J. Touch-down reverse transcriptase-PCR detection of IgV(H) rear-rangement and Sybr—Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. Mol Diagn 2005; 9: 23–34.
- Tobin G, Thunberg U, Johnson A et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003; 101: 4952–4957.
- Aguayo A, O'Brien S, Keating M et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 768–770.